Trial Profile
Prospective pharmacodynamic study on patients with moderate, active Crohn's disease treated with Rifaximin-EIR 400 mg tablets
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2013
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms RETIC-PD
- Sponsors Alfa Wassermann SpA
- 07 Mar 2012 New trial record